Welcome to our dedicated page for Turn Therapeutics SEC filings (Ticker: TTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. While no specific filings are listed in the provided data, Turn’s public communications reference its status as a Nasdaq-listed company and describe a direct listing structure used to enter the public markets.
For a company like Turn Therapeutics, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on clinical programs such as GX-03 for moderate to severe atopic dermatitis, late-stage efforts in onychomycosis, and vaccine initiatives based on its PermaFusion delivery platform. These reports often include discussions of research and development spending, risk factors related to clinical trials and regulatory pathways, and descriptions of commercial agreements, such as the global supply, development, and license agreement with Medline.
Other important SEC documents for a Nasdaq-listed biotechnology company can include current reports on Form 8-K, which may disclose material events like new strategic partnerships, changes to the Board of Directors, or significant financing arrangements. Filings related to equity financing structures, such as the GEM Global Yield agreement and share purchase agreements referenced in company updates, are also commonly detailed in SEC submissions.
On Stock Titan, Turn Therapeutics filings are supplemented with AI-powered summaries designed to explain key sections of lengthy documents in clear language. These tools can help users quickly understand complex topics such as clinical development disclosures, collaboration terms, and capital strategy without reading every page. As new TTRX filings are made available through EDGAR, this page can serve as a starting point for reviewing the company’s regulatory and financial reporting history.
Turn Therapeutics Inc. reported that GEM Yield Bahamas Limited exercised in full a previously issued warrant to acquire common stock using a cashless exercise feature. The warrant, originally issued on October 8, 2025, covered 1,192,207 shares, which represented 4% of Turn Therapeutics’ fully diluted outstanding shares as of that date and carried an exercise price of $5.03 per share.
Because the defined Per Share Market Value exceeded the warrant price, GEM elected the cashless exercise mechanism, and on August 13, 2026 Turn Therapeutics issued 579,664 shares of common stock to GEM. The company states that this unregistered issuance relied on the Section 4(a)(2) exemption under the Securities Act, based on GEM’s status as an accredited investor under Regulation D.
Turn Therapeutics Inc. entered into securities purchase agreements with certain accredited investors, primarily existing series and seed investors, to complete a private equity financing. The company agreed to issue and sell 135,000 shares of common stock at a purchase price of $10.00 per share, resulting in aggregate gross proceeds of $1.35 million.
The transaction was structured as a private placement relying on the registration exemptions under Section 4(a)(2) of the Securities Act of 1933 and Regulation D for transactions not involving a public offering. Turn Therapeutics also granted the investors registration rights for these shares, enabling potential future resale under a registration statement.
Turn Therapeutics Inc., a clinical-stage dermatology-focused biotech, reported a net loss of $6.8 million for the six months ended June 30, 2026, compared with $1.6 million a year earlier, driven by higher R&D spending, stock-based compensation and a sizable non-cash loss on derivatives.
Cash and cash equivalents rose to $10.3 million from $5.1 million at December 31, 2025, aided by a $7.0 million Avenue Capital term loan and collection of a $1.1 million subscription receivable. However, total liabilities increased to $16.3 million, including $6.1 million of derivative liability and $6.1 million of secured long-term debt, leaving stockholders’ equity at only $0.7 million.
The company disclosed an accumulated deficit of $29.2 million and stated that expected cash needs raise substantial doubt about its ability to continue as a going concern, despite estimating its current cash can fund GX‑03 development in atopic dermatitis into the third quarter of 2027. Turn is advancing its lead topical candidate GX‑03 in an adaptive Phase 2 AD trial, expanding enrollment after an interim analysis with no major safety concerns, and is preparing additional programs in onychomycosis and hidradenitis suppurativa while relying on future equity, debt and partnering to finance operations.
Turn Therapeutics reported second-quarter 2026 results and provided clinical updates for lead topical candidate GX-03 in atopic dermatitis. In an interim Phase 2 analysis using final Stage 2 criteria, GX-03 showed treatment separation from vehicle across four efficacy endpoints, including 61.5% vs 8.3% of patients achieving clear or almost clear skin at Week 4 and 46.2% vs 8.3% achieving complete EASI clearance at Week 8. Stage 1 showed a favorable safety profile with no serious adverse events or discontinuations.
Based on these data, Stage 2 enrollment was expanded to approximately 120–135 patients with planned statistical power of at least 99.8% across the four endpoints, with enrollment expected to complete in the fourth quarter of 2026. The company also plans a Phase 2a study of GX-03 in hidradenitis suppurativa with about 60 patients, targeting first patient dosing in the second quarter of 2027.
Financially, Turn reported a Q2 2026 net loss of $5,849,734 and basic and diluted net loss per share of $0.20. Cash and cash equivalents were $10,288,510 as of June 30, 2026, and the company expects its cash to fund operations into the third quarter of 2027.
Turn Therapeutics Inc. presents an updated investor overview centered on GX-03, a first-in-class, non-systemic immunomodulation therapy delivered via its PermaFusion platform to target IL‑36 and related cytokines in inflammatory diseases including moderate to severe atopic dermatitis (AD), onychomycosis and hidradenitis suppurativa.
In an ongoing Phase 2 AD trial (planned N = ~ 120-135), a Stage 1 subgroup with baseline PP‑NRS ≥ 7 (GX‑03 n=13, vehicle n=12) showed week‑4 vIGA‑AD success in 61.5% of GX‑03 patients versus 8.3% on vehicle, and EASI‑75 in 69.2% versus 25.0%. Safety data include over 200,000+ patients previously treated with GX‑03 in other indications with zero reported adverse events, plus Phase 2 Stage 1 results showing only one non‑severe adverse event in each arm.
Planned milestones, subject to successful completion of each phase and capital availability, include a Phase 2 AD topline readout in Q4 2026, Phase 3 initiations in AD and onychomycosis in 2027, and a Phase 2a trial in HS. A financial snapshot shows cash of $11 as of March 31, 2026, cash runway into Q3 2027, current G&A burn of ~$250K per month, total capital raised of ~$29M, and 17 issued patents with coverage through 2040.
Turn Therapeutics provided a detailed update on its adaptive Phase 2 trial of GX-03 for atopic dermatitis, based on a comprehensive interim analysis. GX-03 showed clinically meaningful efficacy across a broader range of disease severity than originally expected, including patients with EASI scores of 1.1–7.0, which are typically considered mild-to-moderate.
In this EASI 1.1–7.0 subgroup, Week 4 vIGA-AD Success was 71.4% for GX-03 versus 33.3% for vehicle, and Week 8 EASI-100 was 35.7% versus 11.1%. A representative enriched subgroup (baseline EASI ≥1.1 and PP-NRS ≥7) also showed strong separation, with Week 4 vIGA-AD Success of 61.5% for GX-03 versus 8.3% for vehicle.
The final Stage 2 design will enroll about 120–135 patients across the full EASI spectrum, stratified by baseline severity and evaluated on four prespecified efficacy endpoints using the FDA-recognized Hochberg multiple testing procedure. No treatment-related serious adverse events or discontinuations have been reported, and GX-03 continues to show a favorable safety and tolerability profile. Turn Therapeutics anticipates completing enrollment in the fourth quarter of 2026 and states it is capitalized to fund the study and operations through the third quarter of 2027.
Turn Therapeutics director Martin William Dewhurst received a grant of stock options covering 71,666 shares of Common Stock at an exercise price of $5.75 per share. The options vest in twelve equal monthly installments beginning on June 30, 2026 and expire on June 4, 2036.
Following this award, he holds 71,666 stock options directly, all tied to continued employment and the terms of the 2025 Omnibus Incentive Plan.
Turn Therapeutics director Andrew Gengos received a grant of stock options covering 95,000 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments starting on June 30, 2026, contingent on his continued employment under the company’s 2025 Omnibus Incentive Plan. This is a compensation-related award, not an open-market share purchase or sale.
Turn Therapeutics Inc. director Arthur F. Golden received a grant of stock options for 89,584 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments beginning on June 30, 2026, contingent on continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this award, Golden holds 89,584 option-based rights directly.
Turn Therapeutics Inc. director Kester Kent Edward received a grant of stock options covering 83,334 shares of Common Stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036.
The option award vests in twelve equal monthly installments on the last day of each month, beginning June 30, 2026, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this grant, the reporting person holds 83,334 stock options directly.